Medicine and Dentistry
Biological Marker
10%
Biopsy Technique
10%
Bladder
6%
Bone Metastasis
6%
Bone Scintigraphy
5%
Brachytherapy
20%
Breast Cancer
10%
Cancer
19%
Carcinoma
26%
Cardiovascular System
5%
Castration Resistant Prostate Cancer
6%
Cervical Cancer
49%
Cervix
13%
Chemoradiotherapy
9%
Clinical Trial
9%
Colorectal Carcinoma
5%
Computer Assisted Tomography
24%
Coronary Artery Disease
12%
Coronary Circulation
7%
Diagnosis
17%
Disease Free Survival
6%
Diseases
38%
Distant Metastasis
9%
Dosimetry
8%
Drug Megadose
7%
External Beam Radiotherapy
5%
Fluorine-18
28%
Fluorodeoxyglucose
26%
Fluorodeoxyglucose F 18
50%
Gallium 68
26%
Health Care Cost
5%
Heart Muscle Blood Flow
16%
Heart Muscle Perfusion
7%
Implant
5%
Indium 111
5%
Intensity Modulated Radiation Therapy
9%
Liver Metastasis
5%
Low Drug Dose
7%
Lung
9%
Lung Cancer
5%
Lutetium 177
13%
Lymph Node
14%
Lymph Node Metastasis
9%
Magnetic Resonance Imaging
20%
Malignant Neoplasm
17%
Metabolism
5%
Metastatic Carcinoma
20%
Molecular Imaging
9%
Myocardial Perfusion Imaging
6%
Myocardium
6%
Neoplasm
93%
Neuroendocrine Tumor
27%
Non Small Cell Lung Cancer
10%
Nuclear Medicine
14%
Oncology
15%
Overall Survival
17%
Paraaortic Lymph Node
6%
Pediatrics
8%
Pelvis
28%
Peptide Receptor
9%
Platelet
5%
Polyethylene Terephthalate
67%
Positron Emission Tomography
100%
Positron Emission Tomography - Magnetic Resonance Imaging
7%
Positron Emission Tomography-Computed Tomography
83%
Primary Tumor
8%
Prognostic Factor
8%
Progression Free Survival
9%
Prostate Cancer
21%
Prostate Specific Membrane Antigen
13%
Pulmonary Embolism
7%
Radiation Therapy
49%
Radioactive Tracer
19%
Radioisotope
10%
Radioligand
5%
Radiology
7%
Radionuclide Therapy
10%
Radiopharmaceutical
9%
Receptor
6%
Recurrent Disease
21%
Scintigraphy
21%
Single-Photon Emission Computed Tomography
9%
Solid Malignant Neoplasm
5%
Somatostatin Receptor
11%
Squamous Cell Carcinoma
5%
Standardized Uptake Value
12%
Surgery
6%
Technetium-99
12%
Tetraxetan
7%
Thyroid Gland
5%
Treatment Planning
10%
Treatment Response
8%
Uterine Cancer
9%
Uterine Cervix
12%
Uterine Cervix Carcinoma
10%
Keyphrases
18F-FDG PET-CT
19%
18F-fluorodeoxyglucose (18F-FDG)
13%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
17%
Brachytherapy
16%
Breast Cancer
8%
Cervical Cancer
47%
Cervical Carcinoma
28%
Chemotherapy
12%
Cisplatin
5%
Clinical Application
6%
Clinical Outcomes
7%
Clinical Trials
6%
Cold Pressor
5%
Computed Tomography
20%
Concurrent Chemotherapy
6%
Confidence Interval
7%
Coronary Artery Disease
8%
Disease-free Survival
7%
Distant Metastasis
12%
Dosimetry
7%
Endometrial Cancer
6%
FDG PET-CT
5%
FDG Uptake
6%
Fluoro
7%
Fluorodeoxyglucose
17%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
30%
Gallium-68
8%
HDR Brachytherapy
5%
High Dose
6%
Imaging Modalities
5%
Imaging Studies
5%
Intensity-modulated Radiation Therapy
7%
Intracavitary
7%
Invasive Cervical Cancer
6%
Irradiation
26%
Left Ventricular Function
6%
Liver
10%
Locally Advanced Cervical Cancer
5%
Lung
7%
Lung Cancer
5%
Lutetium-177 (177Lu)
14%
Lymph Node Metastasis
6%
Magnetic Resonance Imaging
11%
Malignancy
5%
Metabolic Tumor Volume
5%
Metastasis
6%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
7%
Metastatic Disease
6%
Molecular Imaging
8%
Multivariate Analysis
5%
Myocardial Blood Flow
17%
Myocardial Flow Reserve
6%
Myocardial Perfusion
6%
National Oncologic PET Registry
5%
Neuroendocrine Tumor
19%
Non-small Cell Lung Cancer (NSCLC)
8%
Nuclear Medicine
12%
Oncologic
7%
Oncology
5%
Overall Survival
17%
Para-aortic Lymph Node
5%
Patient Management
6%
Pelvic Lymph Nodes
5%
Pelvis
8%
Peptide Receptor Radionuclide Therapy
11%
Perfusion
7%
PET Image
6%
PET Imaging
11%
PET-MRI
10%
Phase II Study
6%
Positron Emission Tomography
70%
Positron Emission Tomography-computed Tomography (PET-CT)
66%
Positron Emission tomography-CT
6%
Primary Tumor
8%
Prognostic Factors
10%
Progression-free Survival
10%
Prostate Cancer
9%
Prostate-specific Antigen
16%
Pulmonary Embolism
5%
Radiation Dose
8%
Radiation Therapy
19%
Radiation Therapy Oncology Group
7%
Radioligand Therapy
5%
Radionuclides
6%
Radiopharmaceuticals
11%
Radiotherapy
15%
Radiotracer
6%
Recurrent Disease
6%
Scintigraphy
9%
Single-photon Emission Computed Tomography (SPECT)
12%
Somatostatin Receptor
6%
Stage IB
6%
Standardized Uptake Value
14%
SUVmax
15%
Technetium-99m
10%
Tumor
51%
Tumor Response
6%
Tumor Size
5%
Tumor Volume
6%
Whole-body
6%